Evidence map›Paper›PMID 40630567›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Immune Checkpoint Inhibitors as Independent and Synergistic Drivers of SJS/TEN: An Analysis of FAERS.

Eric Milan Mukherjee, Dodie Park, Amir Asiaee, Matthew S Krantz, Cosby A Stone, Michelle Martin-Pozo, Elizabeth Phillips

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Eric Milan MukherjeeDepartment of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0001-8715-1378
Dodie ParkCenter for Drug Safety and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Amir AsiaeeDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0002-5317-9820
Matthew S KrantzCenter for Drug Safety and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0001-7589-9127
Cosby A StoneCenter for Drug Safety and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0002-1888-4188
Michelle Martin-PozoCenter for Drug Safety and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0002-1526-9569
Elizabeth PhillipsCenter for Drug Safety and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0002-7623-3383

Funding

NATIENS: A Phase III Randomized Double Blinded Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisU01AI154659 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2020 to 2025
$15.5M
Understanding and preventing HLA-associated drug reactionsP50GM115305 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2015 to 2019
$13.0M
Genetic risk and long-term outcomes associated with Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in survivorsR01HG010863 · NHGRI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2019 to 2022
$3.1M
HIV-associated Tuberculosis Training Program (HATTP)D43TW010559 · FIC · UNIVERSITY OF CAPE TOWN · PI Graeme Ayton Meintjes · 2017 to 2026
$3.0M
Immune-mediated adverse drug reactions to HIV and TB treatments in South Africa: predict, prevent and improve long-term outcomes (IMARI SA study)R01AI152183 · NIAID · UNIVERSITY OF CAPE TOWN · PI MEINTJES, GRAEME AYTON, PHILLIPS, ELIZABETH · 2020 to 2025
$1.6M
Single Cell definition of pathogenic T cells in Drug-induced Stevens-Johnson-Syndrome/Toxic epidermal necrolysisR21AI139021 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2018 to 2019
$435k
A Translational Bioinformatics Approach for Phenotyping and Genetic Risk of Severe Cutaneous Adverse Drug ReactionsK08AI185260 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Matthew Steven Krantz · 2025 to 2026
$373k
FIC NIH HHS D43 TW010559NHGRI NIH HHS R01 HG010863NIAID NIH HHS K08 AI185260NIAID NIH HHS L30 AI186122NIAID NIH HHS R01 AI152183NIAID NIH HHS R21 AI139021NIAID NIH HHS U01 AI154659NIGMS NIH HHS P50 GM115305
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Checkpoint InhibitorsFAERSPharmacovigilanceSevere Cutaneous Adverse ReactionsStevens-Johnson SyndromeToxic Epidermal Necrolysis

Identifiers

PMID40630567
PMCPMC12236933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.